Deltex Medical Regulatory News (DEMG)

23 February 2016

Deltex Medical Group plc

("Deltex Medical" or "the Company")

Result of the Open Offer

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), is pleased to announce that it has received valid acceptances from Qualifying Shareholders in respect of 10,693,408 Open Offer Shares, including applications for 6,303,861 Open Offer Shares under the Excess Application Facility. This represents approximately 57.0 per cent. of the maximum Open Offer Shares available under the Open Offer. Please note that all terms in this announcement have the same meaning as in the Circular sent to Shareholders on 8 February 2016.

The Company has therefore raised £2.67 million (before expenses and Amati Loan Note repayment) through the Placing, Open Offer and Loan Notes subscription which will, subject to the approval of the Placing and the Open Offer by Shareholders and Admission, enable a portion of the Loan Notes proceeds to be used to repay the Amati Loan Note in full.

The Placing and the Open Offer are subject to the approval of Shareholders at the General Meeting which has been convened for 10.00 a.m. Thursday, 25 February 2016 at which a resolution to enable the Placing and the Open Offer to proceed will be proposed.

Admission is expected to become effective and dealings in the Placing Shares and the 10,693,408 Open Offer Shares will commence at 8.00 a.m. on 26 February 2016.

Upon Admission, the Company's total issued share capital will be 258,153,394 Ordinary Shares and the Company does not hold any shares in treasury. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:-

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

During 2013, the Company launched the CardioQ-ODM+ monitor that offers clinicians both of the two best-established technologies, Deltex Medical's ODM technology as well as Pulse Pressure Waveform Analysis ('PPWA') in one monitor. This allows clinicians to have unique real time insights into each of flow, pressure and resistance, the three pillars of haemodynamics.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and over 600,000 patients have been treated to date using Deltex Medical's single patient disposable probes.